References
- Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333
- Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839–855
- Antoine F, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007;22:616–622
- Kenemans P, Bundred NJ, Foidart JM, et al LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized non inferiority trial. Lancet Oncol 2009;10:135–146
- Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–255
- Kontos M, Agbaje OF, Rymer J, Fentiman IS. What can be done about hot flushes after treatment for breast cancer? Climacteric 2010;13:4–21
- Saslow D. HRT raises recurrence risk among breast cancer survivors. US Department of Health and Human Services. Women's Newsletter, March 31, 2008. http://www.healthfinder.gov/newsletters/women033108.asp